Giselle Almeida Gonzalez
Researcher
Also affiliated: Arkansas Children's Hospital (2021–2026)
Unknown Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
Giselle Almeida Gonzalez is a researcher at the University of Arkansas for Medical Sciences whose work focuses on the molecular mechanisms underlying pediatric acute megakaryoblastic leukemia (AML). Her research investigates how epigenetic alterations, specifically DNA methylation patterns, contribute to the development and progression of high-risk pediatric AML. Almeida Gonzalez has studied the role of specific gene fusions, such as CBFA2T3-GLIS2, in reprogramming cellular pathways that lead to resistance against targeted therapies like CDK8 inhibitors. Her publications explore how these epigenetic changes create vulnerabilities that may be therapeutically targeted. She has collaborated with researchers including Samrat Roy Choudhury, Arundhati Chavan, and Jason E. Farrar on these investigations. Almeida Gonzalez has published four papers, with an h-index of 1 and a total of 5 citations.
Metrics
- h-index: 1
- Publications: 4
- Citations: 5
Selected Publications
-
Abstract 3496: Epigenetic repurposing by CBFA2T3-GLIS2 reveals a druggable DNA methylation axis in high-risk pediatric AML vulnerability in pediatric AML (2026)
-
Abstract PR006: CBFA2T3–GLIS2 fusion reprograms enhancer-linked DNA methylation to enforce apoptotic resistance and defines an epigenetic vulnerability in pediatric AML (2026)
-
Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia (2025)
-
Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors (2021)
Collaboration Network
Top Collaborators
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia
- Abstract PR006: CBFA2T3–GLIS2 fusion reprograms enhancer-linked DNA methylation to enforce apoptotic resistance and defines an epigenetic vulnerability in pediatric AML
- Abstract 3496: Epigenetic repurposing by CBFA2T3-GLIS2 reveals a druggable DNA methylation axis in high-risk pediatric AML vulnerability in pediatric AML
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia
- Abstract PR006: CBFA2T3–GLIS2 fusion reprograms enhancer-linked DNA methylation to enforce apoptotic resistance and defines an epigenetic vulnerability in pediatric AML
- Abstract 3496: Epigenetic repurposing by CBFA2T3-GLIS2 reveals a druggable DNA methylation axis in high-risk pediatric AML vulnerability in pediatric AML
- Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia
- Abstract PR006: CBFA2T3–GLIS2 fusion reprograms enhancer-linked DNA methylation to enforce apoptotic resistance and defines an epigenetic vulnerability in pediatric AML
- Abstract 3496: Epigenetic repurposing by CBFA2T3-GLIS2 reveals a druggable DNA methylation axis in high-risk pediatric AML vulnerability in pediatric AML
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia
- Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia
- Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia
- Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia
Similar Researchers
Based on overlapping research topics